# Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

> **NCT00117650** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 289 (actual)

## Conditions studied

- Intermittent Claudication
- Peripheral Vascular Disease
- Atherosclerosis

## Interventions

- **BIOLOGICAL:** Ad2/HIF-1α/VP16
- **BIOLOGICAL:** Ad2/HIF-1α/VP16
- **BIOLOGICAL:** Ad2/HIF-1α/VP16
- **OTHER:** Saline (Placebo Control)

## Key facts

- **NCT ID:** NCT00117650
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2008-09
- **Final completion:** 2010-03
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117650, "Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00117650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*